Apogee net loss widens to $85.85 million in Q2 FY26; R&D expenses rise to $67.3 million
Reuters2026/08/10 11:06- Apogee Therapeutics posted a Q2 2026 net loss of $85.85 million, widening from $66.1 million a year earlier.
- R&D expenses rose 20.82% to $67.3 million, while G&A costs climbed 39.38% to $24.34 million, both versus Q2 2025.
- Cash, cash equivalents and marketable securities totaled $1.3 billion at June 30, 2026, up from $621.2 million a year earlier.
- June 2026 deal calls for AbbVie to buy Apogee for $135.11 per share in cash, valuing equity at about $10.9 billion; closing expected Q3 2026.
- Phase 2 APEX Part B met endpoints; 65.9% on mid-dose zumilokibart achieved EASI-75 at Week 16, supporting planned Phase 3 start this year.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Spot bitcoin ETFs pull in $987 million last week as institutional demand recovers
Silver Price Forecast: XAG/USD dips below $66.00 and hints at a bearish “H&S”
Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well
Swiss pharmaceutical giant Novartis has suffered another clinical trial setback—within one week, the company’s second major drug candidate has failed in a late-stage study. This latest disappointment concerns its potential blockbuster heart disease drug pelacarsen.
Crypto prices
More
